Merck Europe B.V.
12 products tracked · names used in filings: Merck Europe B.V.
Upcoming milestones
No upcoming milestones listed.
Recent milestones
No recent milestones.
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Ogsiveo nirogacestat | Authorised | 2025-08-14 |
| 🇪🇺 | Ezmekly mirdametinib | Authorised | 2025-07-17 |
| 🇪🇺 | Tepmetko tepotinib | Authorised | 2022-02-16 |
| 🇪🇺 | Bavencio avelumab | Authorised | 2017-09-18 |
| 🇪🇺 | Mavenclad cladribine | Authorised | 2017-08-22 |
| 🇪🇺 | Pergoveris follitropin alfa;lutropin alfa | Authorised | 2007-06-25 |
| 🇪🇺 | Erbitux cetuximab | Authorised | 2004-06-29 |
| 🇪🇺 | Ovitrelle choriogonadotropin alfa | Authorised | 2001-02-02 |
| 🇪🇺 | Luveris lutropin alfa | Authorised | 2000-11-29 |
| 🇪🇺 | Cetrotide cetrorelix | Authorised | 1999-04-12 |
| 🇪🇺 | Rebif interferon beta-1a | Authorised | 1998-05-03 |
| 🇪🇺 | GONAL-f follitropin alfa | Authorised | 1995-10-20 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.